Accéder au contenu
Merck

Effects of Qidantang Granule on early stage of diabetic kidney disease in rats.

Aging (2022-06-14)
Tengfei Wu, Xinyu Yang, Yilei Cong, Shisi Xia, Bowen Liu, Ran Zou, Juanhua Zeng, Hua Yang
RÉSUMÉ

Diabetic kidney disease (DKD), is one of the most common vascular diseases caused by diabetes, eventually progressing into glomerular sclerosis. Qidantang Granule is a traditional Chinese medicine that is commonly used for DKD. However, there is still no experimental evidence for its effectiveness on DKD. 8-week-old Sprague Dawley male rats were fed on high-fat and high-sugar diet for 4 weeks, and then intraperitoneally injected with 35 mg/kg streptozotocin (STZ) to induce diabetes. Diabetic rats were randomly divided into three groups, and orally administrated with vehicle, 50 mg/kg or 200 mg/kg Qidantang Granule respectively, once daily for 9 weeks. Qidantang Granule effectively reduced food and water intake, body weight and fasting blood glucose, decreased inflammation and oxidative stress, ameliorated renal injury through suppressing PI3K signaling pathway in STZ-induced DKD rats. Our results provide experimental evidence to demonstrate the pharmacological mechanism of Qidantang Granule in the treatment of DKD.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-PI3K P85 antibody, Rabbit monoclonal, clone SP62, recombinant, expressed in proprietary host, affinity isolated antibody